Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cea.70098 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative short-term efficacy of Janus kinase 1 inhibitors and anti-interleukin-13 antibodies in atopic dermatitis: a retrospective cohort analysis based on real-world data.
Front Immunol
August 2025
Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Introduction: Molecular targeted therapies, including advanced atopic dermatitis (AD) treatment with Janus kinase 1 inhibitors (JAK1i) and anti-interleukin-13 antibodies (IL-13Ab), are emerging as effective options. However, the predictive biomarkers for treatment responses remain unclear. Therefore, this study compared the short-term efficacy of JAK1i and IL-13Ab and explored relevant biomarkers.
View Article and Find Full Text PDFDrug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish Cohort.
Acta Derm Venereol
August 2025
Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Dermatology, Karolinska University Hospital, Stockholm, Sweden.
Real-world data on the drug survival of established and emerging treatment options in atopic dermatitis provide a comprehensive measure of the efficacy and tolerability of these interventions, which may enable improvements in clinical management. This study aimed to describe the drug survival, with associated predictors, of treatment with abrocitinib, baricitinib, cyclosporine, dupilumab, methotrexate, tralokinumab, and upadacitinib among patients with atopic dermatitis in Sweden who were recruited into the multicentre prospective SwedAD cohort between January 2017 and April 2024. A total of 1,194 patients were included with a total of 1,486 treatment episodes.
View Article and Find Full Text PDFEffectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort Study.
Dermatitis
July 2025
Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
Atopic dermatitis (AD) affecting the head and neck (H&N) area poses a clinical challenge due to the unique anatomical and physiological features of this region. Despite its well-documented impact on quality of life (QoL), evidence on the effectiveness of tralokinumab in treating AD specifically in the H&N area remains limited. To assess the clinical outcomes of tralokinumab in AD patients with H&N involvement, informing clinical decision-making and improving patient care.
View Article and Find Full Text PDFClinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16.
Dermatol Ther (Heidelb)
July 2025
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA.
Introduction: Investigator's Global Assessment (IGA) of clear/almost clear (0/1) skin is a high standard to achieve after 16 weeks of treatment for patients with moderate-to-severe atopic dermatitis (AD) and does not capture clinically meaningful responses in other patient domains, such as improvement in itch and/or quality of life. To better evaluate the effect of tralokinumab in adolescents, we assessed the clinically meaningful impact of tralokinumab versus placebo in patients who did not meet IGA 0/1 at week 16 without rescue medication in ECZTRA 6.
Methods: These post hoc analyses included adolescents from the ECZTRA 6 (NCT03526861) phase 3 trial who did not achieve IGA 0/1 at week 16 without rescue medication (referred to as IGA >1).
Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy.
Dermatitis
July 2025
From the Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
The transition of blood biomarkers has not been precisely examined in real-world treatments with anti-interleukin (IL)-13 antibodies for atopic dermatitis (AD). To evaluate the transition of blood biomarkers during 24-week treatment with lebrikizumab or tralokinumab for patients with AD in real-world settings, stratified by the presence or absence of prior systemic therapy. We conducted a retrospective study of Japanese patients with AD who received lebrikizumab ( = 148) or tralokinumab ( = 173).
View Article and Find Full Text PDF